Parés, Albert

Simplified criteria for the diagnosis of autoimmune hepatitis

Hennes, E. M., Zeniya, M., Czaja, A. J., Parés, A., Dalekos, G. N., Krawitt, E. L., Bittencourt, P. L., Porta, G., Boberg, K. M., Hofer, H., et al. (2008) · Hepatology

Liver Diseases and ImmunityIgG4-Related and Inflammatory Diseases

Cited by 1,901

EASL Clinical Practice Guidelines on nutrition in chronic liver disease

Merli, M., Berzigotti, A., Zelber-Sagi, S., Dasarathy, S., Montagnese, S., Genton, L., Plauth, M., & Parés, A. (2019) · Journal of Hepatology

Liver Disease and TransplantationClinical Nutrition and Gastroenterology

Cited by 1,130

Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid

Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 756

Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid

Hirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 576

Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study

Lammers, W. J., van Buuren, H. R., Hirschfield, G. M., Janssen, H. L. A., Invernizzi, P., Mason, A. L., Ponsioen, C. Y., Floreani, A., Corpechot, C., Mayo, M. J., et al. (2014) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 498

Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy

Lammers, W. J., Hirschfield, G. M., Corpechot, C., Nevens, F., Lindor, K. D., Janssen, H. L. A., Floreani, A., Ponsioen, C. Y., Mayo, M. J., Invernizzi, P., et al. (2015) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 441

Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis

Harms, M. H., van Buuren, H. R., Corpechot, C., Thorburn, D., Janssen, H. L. A., Lindor, K. D., Hirschfield, G. M., Parés, A., Floreani, A., Mayo, M. J., et al. (2019) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 289

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis

Kowdley, K. V., Luketic, V., Chapman, R., Hirschfield, G. M., Poupon, R., Schramm, C., Vincent, C., Rust, C., Parés, A., Mason, A., et al. (2018) · Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 281

Effects of long-term rifampicin administration in primary biliary cirrhosis

Bachs, L., Parés, A., Elena, M., Piera, C., & Rodés, J. (1992) · Gastroenterology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 235

COMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS

Bachs, L., Elena, M., Parés, A., Piera, C., & Rodés, J. (1989) · The Lancet

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 231

Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial

de Vries, E., Bolier, R., Goet, J., Parés, A., Verbeek, J., de Vree, M., Drenth, J., van Erpecum, K., van Nieuwkerk, K., van der Heide, F., et al. (2021) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 224

Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase

Murillo Perez, C. F., Harms, M. H., Lindor, K. D., van Buuren, H. R., Hirschfield, G. M., Corpechot, C., van der Meer, A. J., Feld, J. J., Gulamhusein, A., Lammers, W. J., et al. (2020) · American Journal of Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 188

Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis

Guañabens, N., Parés, A., Ros, I., Caballería, L., Pons, F., Vidal, S., Monegal, A., Peris, P., & Rodés, J. (2005) · Journal of Hepatology

Liver Diseases and ImmunityBone health and osteoporosis research

Cited by 179

Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study

Trivedi, P. J., Lammers, W. J., van Buuren, H. R., Parés, A., Floreani, A., Janssen, H. L. A., Invernizzi, P., Battezzati, P. M., Ponsioen, C. Y., Corpechot, C., et al. (2016) · Gut

Liver Diseases and ImmunityHepatocellular Carcinoma Treatment and Prognosis

Cited by 178

Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis

Guañabens, N., Cerdá, D., Monegal, A., Pons, F., Caballería, L., Peris, P., & Parés, A. (2010) · Gastroenterology

Liver Diseases and ImmunityBone health and osteoporosis research

Cited by 142

Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis

Vesterhus, M., Hov, J. R., Holm, A., Schrumpf, E., Nygård, S., Godang, K., Andersen, I. M., Næss, S., Thorburn, D., Saffioti, F., et al. (2015) · Hepatology

Liver Diseases and ImmunityLiver Disease Diagnosis and Treatment

Cited by 138

Osteoporosis in chronic liver disease

Guañabens, N., & Parés, A. (2018) · Liver International

Bone health and osteoporosis researchBone Metabolism and Diseases

Cited by 128

Alendronate Is More Effective Than Etidronate for Increasing Bone Mass in Osteopenic Patients With Primary Biliary Cirrhosis

Guañabens, N., Parés, A., Ros, I., Alvarez, L., Pons, F., Caballería, L., Monegal, A., de Osaba, J. M. M., Roca, M., Peris, P., et al. (2003) · American Journal of Gastroenterology

Bone health and osteoporosis researchLiver Diseases and Immunity

Cited by 119

Portal hypertension in primary biliary cirrhosis

Navasa, M., Parés, A., Bruguera, M., Caballería, J., Bosch, J., & Rodés, J. (1987) · Journal of Hepatology

Liver Diseases and ImmunityLiver Disease and Transplantation

Cited by 119

Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response

Reig, A., Sesé, P., & Parés, A. (2018) · American Journal of Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 115

Incidence, Risk Factors, and Survival of Hepatocellular Carcinoma in Primary Biliary Cirrhosis: Comparative Analysis from Two Centers†

Cavazza, A., Caballería, L., Floreani, A., Farinati, F., Bruguera, M., Caroli, D., & Parés, A. (2009) · Hepatology

Liver Diseases and ImmunityHepatocellular Carcinoma Treatment and Prognosis

Cited by 114

A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA

Hirschfield, G. M., Beuers, U., Kupcinskas, L., Ott, P., Bergquist, A., Färkkilä, M., Manns, M. P., Parés, A., Spengler, U., Stiess, M., et al. (2021) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 108

Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid

Lens, S., Leoz, M., Nazal, L., Bruguera, M., & Parés, A. (2014) · Liver International

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 107

Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls

Murillo Perez, C. F., Fisher, H., Hiu, S., Kareithi, D., Adekunle, F., Mayne, T., Malecha, E., Ness, E., van der Meer, A. J., Lammers, W. J., et al. (2022) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 107